Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

NCT06664411 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.

NCT NCT06664411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06664411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Lead sponsor
Navy General Hospital, Beijing
Phase
Phase 2
Overall status
Recruiting
Start date
September 24, 2024
Completion date
December 31, 2030
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma